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Abstract
Background: Due to its extremely high strength, the interaction between biotin and (strept)avidin
has been exploited for a large number of biotechnological applications. Site-specific biotinylation of
proteins in vivo can be achieved by co-expressing in mammalian cells the protein of interest fused
to a 15 amino acid long Biotin Acceptor Peptide (BAP) and the bacterial biotin-protein ligase BirA,
which specifically recognizes and attaches a biotin to the single lysine residue of the BAP sequence.
However, this system is mainly based on the contemporaneous use of two different plasmids or on
induction of expression of two proteins through an IRES-driven mechanism.
Results: We developed a single bigenic plasmid that contains two independent transcriptional
units for the co-expression of both the protein tagged with BAP and an engineered version of the
BirA enzyme. Upstream of the cDNA encoding BirA, a signal secretion leader sequence was added
to allow translocation of the enzyme to the secretory pathway. Three different recombinant
antibodies in the scFv format, a membrane bound and secretory truncated IgE Fc fragment and a
soluble version of the human IgE high affinity receptor were shown to be efficiently biotinylated and
to maintain their binding properties in immunofluorescence microscopy, flow cytometry and ELISA
assays.
Conclusion: The present study shows the universal applicability to both secretory and membrane
bound proteins of a single bigenic plasmid to induce the site-specific in vivo biotinylation of target
molecules tagged with a short acceptor peptide. These molecules could be easily obtained from
supernatants or extracts of mammalian cells and used for a wide range of biological applications.
Background
Biotin or vitamin H is a small hydrosoluble molecule pro-
duced by plants and a large number of prokaryotic organ-
isms. It is involved in several metabolic pathways,
including gluconeogenesis or fatty acid and amino acid
catabolism, as a carboxyl carrier covalently linked to a spe-
cific lysine residue of a group of decarboxylases. This resi-
due is located in a subunit called biotin carboxyl carrier
protein (BCCP), and biotin is attached in an ATP-depend-
ent reaction by a highly conserved family of biotin-pro-
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tein ligases, the most characterized of which is the BirA
enzyme from E. coli [1-4].
In addition to its physiological relevance, biotin has the
interesting ability to bind to two homologous proteins:
avidin, from the avian egg, and streptavidin, from bacte-
ria. This interaction is the strongest non-covalent binding
known (Kd = 10-15 M) [5]. Taking advantage of this prop-
erty, the interaction biotin-(strept)avidin has been
exploited for a large number of biotechnological applica-
tions [6,7]. Currently, biotinylation of proteins is
achieved by different chemical reactions. The major disad-
vantage of this approach is the uncontrollable binding of
biotin to sites of the target protein that can be important
for its biological activity [8,9].
To overcome this limitation, new approaches that mimic
the physiological biotinylation of proteins have been
developed, using different peptides containing an enzy-
matic biotinylation site [10-12]. One of the most useful
and widely used is a 15 amino acid long peptide (biotin
acceptor peptide or BAP) [13,14] that constitutes a spe-
cific and efficient target for the biotin-protein ligase BirA
of E. coli [15], which attaches covalently one biotin mole-
cule to the single lysine residue within the BAP sequence.
When the BAP peptide is genetically fused to the protein
of interest, it is possible to obtain the protein biotinylated
through two alternatives: in vitro, using the tagged protein
and the purified enzyme [16], or in vivo in mammalian
cells following co-transfection with plasmids encoding
both proteins [15,17,18]. The in vivo approach has the
advantage of producing the tagged protein and the BirA
enzyme at constant rates avoiding purification of both
molecules.
Here we show the universal applicability to both secretory
and membrane bound proteins of immunological interest
of a biotinylation system based on the co-expression of a
target protein and an engineered version of BirA enzyme
encoded by a single bigenic plasmid. Secretory recom-
binant antibody derived molecules, for instance in the
popular scFv format, a membrane bound and secretory
IgE Fc fragment or a soluble version of a membrane recep-
tor were shown to be efficiently biotinylated in vivo, offer-
ing a wide range of biological applications.
Methods
Construction of plasmids
The coding sequence for the BirA enzyme [GenBank:
P06709] was amplified by PCR from genomic DNA of E.
coli K12 strain with oligonucleotides: 5'-TGTGTGCACTC-
GATGAAGGATAACACCGTGCCA-3' (forward) and 5'-
AGACTCGAGTTATTTTTCTGCACTACGCAGGGA-3'
(reverse). The amplified fragment was ligated into ApaLI
and XhoI sites of pUT-sec vector [19] to introduce a secre-
tion signal. The HindIII/XhoI fragment from this plasmid
was ligated into pcDNA3 vector (Invitrogen, Paisley, UK),
obtaining the pcDNA3-sec-BirA plasmid.
The BAP sequence was obtained by annealing and elon-
gating with DNA polymerase I Klenow large fragment
(New England Biolabs, Beverly, MA) the two oligonucle-
otides: 5'-AGCTGGATCCGCCGGAGGCTCTGGAGGCCT-
GAACGATATTTCCGAAGCTCAGAAAAT-3' and 5'-
ATCGAATTCTTAAGAGCCTTCGTGCCATTCGATTTTCT-
GAGCTTCGAAAAT-3'. The resulting fragment encodes a 7
amino acid linker (GSAGGSG) between the protein of
interest and the BAP sequence GLNDIFEAQKIEWHE. This
fragment was inserted into a pcDNA3 vector coding for
the SV5 protein tag [20,21], downstream SV5 between
restriction sites BamHI/EcoRI.
Plasmids coding for scFvP3 and scFv1E10 have been previ-
ously described [22,23]. These plasmids were digested
with HindIII and BspEI restriction enzymes to introduce
the scFvs upstream the SV5-BAP sequence, obtaining the
pcDNA3-scFv-SV5-BAP plasmids. Every time scFvs of dif-
ferent specificities were required, the HindIII/BspEI frag-
ments encoding the scFvs of interest were substituted to
the previous ones.
To clone the transcriptional unit of the BirA gene into the
plasmid codifying for the scFv-SV5-BAP protein, the BglII/
BbsI fragment derived from pcDNA3-sec-BirA was blunted
with Klenow enzyme and inserted into the NruI-digested
scFv-SV5-BAP plasmids, resulting in the bigenic scFv-SV5-
BAP-BirA plasmids.
To construct the bigenic αD1D2-SV5-BAP-BirA plasmid
(αD1D2), the NdeI/BspEI fragment derived from
pcDNA3-sdα [24] was ligated with the scFv-SV5-BAP-BirA
vector, previously digested with the NdeI and BspEI restric-
tion enzymes to remove the scFv.
The sequence coding for the truncated form of IgE anti-
body t-IgE with a SV5 tag (SV5-εCH3CH4) was previously
obtained [25]. The BAP sequence was inserted at the C-ter-
minus of the soluble form (t-sIgE) between BamHI and
EcoRI sites. For the membrane-bound format t-mLIgE,
with the transmembrane domain (TM) at the C-terminus,
both SV5 and BAP tags were cloned at the N-terminus
between ApaLI and BstBI sites, after amplifying the frag-
ment SV5-BAP from the template scFv1E10-SV5-BAP with
oligonucleotides: 5'-TCTGTGCACTCGGAAGGCAAAC-
CAATCCCAAAC-3' and 5'-TCTTTCGAATCTGCACAA-
GAGCCTTCGTGCCATTC-3'. The bigenic SV5-εCH3CH4-
BAP-BirA (t-sIgE) and SV5-BAP-εCH3CH4-TM-BirA (t-
mLIgE) plasmids were obtained as described above for
scFvs.BMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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All constructs are represented in Fig. 1.
Cell culture, transfection and selection
HEK293 and HEK293T/17 cells from American Type Cul-
ture Collection (Rockville, MD, numbers CRL-1573 and
CRL-11268, respectively) were cultured in Dulbecco's
modified Eagle's medium (DMEM, Gibco, Paisley, UK)
supplemented with 10% heat inactivated fetal calf serum
(FCS) (Gibco), 50 µg/ml gentamycin (Gibco) and 2 mM
L-glutamine.
Transient transfections of HEK293T/17 cells and stable
transfections of HEK293 cells were performed essentially
as described by Sambrook et al. [26], using circular or lin-
earized plasmids respectively. To select stable clones, 0,4
mg/ml Geneticin (G418, Gibco) was added to the
medium 24 h after transfection. Selected clones were
screened for their production of biotinylated proteins by
ELISA assay.
RBL-SX38 cells expressing the high-affinity receptor for
IgE (FcεRI) [27] were cultured in DMEM supplemented
with 10% heat inactivated FCS, 50 µg/ml gentamycin, 2
mM L-glutamine, 0,8 mg/ml Geneticin and 3,5 mg/ml
glucose.
The Sp2/0 stable transfectoma displaying the 1E10 idio-
type in the membrane small immune protein (membrane
SIP) format [28] was previously described [22]. Cells were
cultured in RPMI 1640 medium (Gibco) supplemented
with 10% heat inactivated FCS, 50 µg/ml gentamycin, 2
mM L-glutamine, 1 mM sodium piruvate and 0,4 mg/ml
Geneticin.
The A20 stable transfectoma expressing the full human
membrane IgE was previously obtained [28] and cultured
as the Sp2/0 transfectoma above described.
Preparation of samples
Supernatants from transiently transfected cells were col-
lected 48 h post transfection. 24 h before collection, the
culture medium was replaced with a serum-free medium
supplemented with 100 µM biotin (Fluka). To remove
free biotin, after collection supernatants were extensively
dialyzed against PBS.
In the case of stable clones, supernatants were collected
after 24 h of culture in serum-free medium supplemented
with biotin and dialyzed.
Cellular extracts were prepared in TNN lysis buffer (100
mM Tris-HCl, pH 8, 250 mM NaCl, 0.5% NP-40) at 4°C,
supplemented with a Protease Inhibitor Cocktail (PIC,
Sigma) according to manufacturer's instructions, and
were centrifuged at 15,800 × g for 5 min.
Enzyme-linked immunoadsorbent assay (ELISA)
Nunc Immune-Plates Maxi Sorp (Nunc, Denmark) were
coated with the specific ligands in carbonate buffer: 10 µg/
ml chimeric 1E10 and P3 antibodies [29] for scFvP3 and
Representation of the bigenic vector and gene constructs Figure 1
Representation of the bigenic vector and gene constructs. Scheme of the different model target protein constructs 
used. EMPD, TM and Cyto correspond, respectively, to the extracellular membrane proximal, transmembrane and cytoplasmic 
domains of membrane bound t-IgE; green box, 11 amino acid long SV5 tag; red box, 15 amino acid long biotin acceptor peptide 
BAP; sec, secretory signal peptide.BMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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scFv1E10 respectively; 10 µg/ml anti-human IgE antibody
(DAKO) for t-sIgE; 10 µg/ml purified human IgE (Calbio-
chem, Canada) for αD1D2; 1 µg/ml streptavidin (Invitro-
gen) for biotinylated scFv9E1. After 1 h, plates were washed
with PBS-Tween20 0,05% and blocked with PBS-Tween20
0,05%-BSA (bovine serum albumin) 1%. Interactions
were detected using a mouse anti-SV5 monoclonal anti-
body (mAb) (Invitrogen) and, as a secondary antibody, a
horseradish peroxidase (HRP)-conjugated anti-mouse
IgG (γ-chain specific) antibody (Pierce, Rockford, IL),
whereas biotinylation of molecules was checked by using
HRP-conjugated streptavidin (Amersham). All antibodies
were diluted according to the manufacturer's instructions.
Reaction was developed with the 3,3',5,5'-tetramethyl-
benzidine (TMB) reagent (Sigma) and read at 450 nm
with a Microplate 550 reader (BioRad, Hercules, CA).
SDS-PAGE and Western blot
Samples were analyzed by 10% SDS-PAGE under reduc-
ing conditions in Tris-glycine buffer. Following electro-
phoresis, gels were blotted onto PVDF membrane
(Millipore) with standard conditions [30]. Membranes
were blocked with PBS-milk 5% and subsequently incu-
bated with specific antibodies.
To estimate the relative amount of biotinylated versus
non-biotinylated proteins, a gel retardation assay was
used. Samples (dialyzed supernatants or cell extracts)
were boiled for 5 min, incubated for 1 h at 4°C with 1 µg
of purified streptavidin (Invitrogen) and then resolved by
SDS-PAGE under reducing conditions. The resulting com-
plexes were detected by Western blot using an anti-SV5
mAb (Invitrogen) and an HRP-conjugated anti-mouse
IgG (γ-chain specific) antibody (KPL, Kirkegaard and
Perry Laboratories, Gaithersburg, MD), diluted according
to the manufacturer's instructions.
To detect the cytosolic protein NSP5, a guinea pig anti-
NSP5 anti-serum [31] and an HRP-conjugated anti-guinea
pig IgG antibody (KPL) were used.
Flow cytometry assays
The Sp2/0 stable transfectoma expressing the 1E10 mem-
brane SIP was incubated with undiluted dialyzed superna-
tants from scFvP3-expressing transfectoma for 1 h at 4°C,
washed twice with PBS-BSA 3%, and incubated again with
streptavidin-Quantum Dots 655 (Invitrogen), diluted
1:1,000 in PBS-BSA 3%. Streptavidin binding was
detected by FACS with a FACSCalibur flow cytometer
(Beckton Dickinson, Mountain View, CA) and data were
analyzed with the CellQuest software. As negative con-
trols, supernatants containing scFv1E10 or the non-bioti-
nylated scFvP3 were used.
Similarly, RBL-SX38 cells were incubated with superna-
tants from scFv9E1 or t-sIgE-expressing transfectomas. As
negative controls, supernatants with the non-biotinylated
proteins were used.
Cells expressing transiently the t-mLIgE protein were
washed twice with PBS and once with PBS-BSA 3% and
then incubated with streptavidin-Quantum Dots 655 or a
fluorescein isothiocyanate (FITC)-conjugated goat anti-
human IgE (ε-chain specific) antibody (KPL) (diluted
according to the manufacturer's instructions).
Immunofluorescence microscopy
Sp2/0 and A20 transfectomas and RBL-SX38 cells were
plated on poly-L-lysine (Sigma) coated glass coverslips for
15 min, fixed with 3,7% paraformaldehyde for 10 min
and then incubated with supernatants containing the spe-
cific ligand for 1 h at room temperature, washed and incu-
bated with streptavidin-Quantum Dots for 1 h. Samples
were analyzed by confocal microscopy (Axiovert, Carl
Zeiss). As positive controls, FITC-conjugated goat anti-
human IgE (ε-chain specific) antibody (KPL), recognizing
the self-dimerizing εCH4 domain of the membrane SIP, or
the 9E1 mAb followed by a FITC-conjugated goat anti-
mouse IgG (γ-chain specific) antibody (KPL) were used.
Antibodies were diluted as for flow cytometry assays.
Purification of biotinylated molecules
Biotinylated molecules from dialyzed supernatants were
purified using SoftLink™ Soft Release Avidin Resin
(V201B, Promega, Madison, WI, USA) according to the
manufacturer's instructions. Briefly, an appropriate bed
volume of resin was poured into an empty chromatogra-
phy column (BioRad), washed, saturated with 5 mM
biotin and regenerated. After equilibration with modified
TBS buffer (50 mM Tris, 150 mM NaCl, pH 7.9), the
supernatant was loaded and elution performed with 5
mM biotin in equilibration buffer. Fractions of 250 µl
were collected and assayed by Western blot analysis. All
steps were performed at room temperature.
Results
To achieve site-specific biotinylation of proteins within
the secretory pathway, two requirements must be fulfilled:
i) the protein of interest tagged with the appropriate BAP
sequence, and ii) the biotin protein ligase expressed
within the secretory compartment, i.e. the endoplasmic
reticulum (ER).
In all our constructs we have used the BAP sequence GLN-
DIFEAQKIEWHE, fused to either the N- or the C-terminus
of the protein. The cDNA of the BirA enzyme was engi-
neered by adding at the 5' end a sequence encoding a
secretion signal leader peptide [19] to allow translocation
of the enzyme into the ER (sec-BirA). For in vivo biotinyla-BMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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Biotinylation of secretory scFv proteins Figure 2
Biotinylation of secretory scFv proteins. Western blot gel retardation assay of supernatants from cells transiently trans-
fected (A) or stably transfected (B) with the bigenic vector expressing the indicated scFv. (C) Supernatants from stably trans-
fected cells taken at different culture times. Where indicated, cell cultures were supplemented with biotin for 24 h and dialyzed 
samples reacted with streptavidin. (D) ELISA of biotinylated or non-biotinylated scFvP3 (coating chimeric mAb 1E10) and 
scFv1E10 (coating chimeric mAb P3); binding was revealed with anti-SV5 tag mAb or HRP-conjugated-streptavidin. (E) Flow 
cytometry and (F) immunofluorescence microscopy of biotinylated scFvs on cells expressing specific cell-surface ligands. scFvP3 
(left panels) was reacted with cells displaying idiotype 1E10; scFv9E1 (right panels) was reacted with RBL-SX38 expressing 
human FcεRI. Binding was performed with biotinylated (red) or non-biotinylated (violet) scFvs and with Quantum Dots-conju-
gated streptavidin. The green signal corresponds to FITC-conjugated anti-human IgE (ε-chain specific) antibody that recognizes 
the ε-membrane SIP displaying the idiotype.BMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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tion of proteins within the secretory pathway in mamma-
lian cells, we initially co-transfected two plasmids
encoding the tagged protein of interest and the sec-BirA
enzyme. However, since the concomitant expression from
two different plasmids was sometimes not well achieved
(in particular when selecting stable transfectomas), we
constructed a single bigenic plasmid with two different
and independent gene cassettes, one for the sec-BirA
enzyme and the other for the target protein. The two cas-
settes were assembled in the same and the opposite tran-
scriptional orientation. Since the relative orientation of
the two transcriptional units was irrelevant to the expres-
sion and the biotinylation levels of the BAP-tagged pro-
tein (not shown), we arbitrarily chose the vector with the
two cassettes in the same orientation for all the different
molecules tested (listed in Fig. 1).
We first tested our bigenic plasmid system with three dif-
ferent model scFvs  expressed as secretory proteins that
were derived from: i) mAb P3, specific for N-glycolyl-con-
taining gangliosides [32], ii) mAb 1E10, an anti-idiotype
antibody specific for mAb P3 [33] and iii) mAb 9E1, spe-
cific for the α-chain of the human IgE high affinity recep-
tor (FcεRI) [24]. Culture supernatants from transiently
transfected HEK293T/17 cells cultured in the presence of
biotin, were first dialyzed to eliminate free biotin and
then analyzed by Western blot (WB) in a gel retardation
assay in the presence of streptavidin. The complex formed
by streptavidin and biotinylated protein resists SDS-PAGE
conditions and is retarded in relation to the non-bioti-
nylated molecules that do not bind streptavidin. As
shown in Fig. 2A, almost all molecules of the three differ-
ent scFvs were biotinylated, indicating the high efficiency
of the method. For two scFvs, similar analysis was then
repeated with supernatants from stably transfected
HEK293 cells showing similar biotinylation efficiency
(Fig. 2B). In addition, both the expression (around 3–6
µg/ml, data not shown) and the biotinylation levels of
molecules remained almost identical over time, as shown
with samples taken after 2, 7 or 28 days of culture of the
transfectoma expressing the scFv1E10 (Fig. 2C). No signs of
increased cell death were observed for the different trans-
fectomas, indicating that the expression of BirA in the ER
is not toxic for cells.
The binding properties of the biotinylated scFvs  were
assayed by ELISA, and for two of them also by flow cytom-
etry and immunofluorescence assays (Fig. 2D–F), using
cells displaying on their membranes the respective lig-
ands. scFvP3 was tested on cells displaying the 1E10 idio-
type, whereas the scFv9E1 was tested on RBL-SX38 cells that
express the high affinity receptor FcεRI. In both cases, a
clear and ligand-specific binding of the biotinylated mol-
ecules was demonstrated using streptavidin coupled to
Quantum Dots, which provided a stronger signal com-
pared to streptavidin conjugated with traditional fluoro-
phores (not shown).
We also co-expressed with sec-BirA a recombinant trun-
cated version of the human IgE heavy chain protein either
in its secretory or membrane bound form [25], to investi-
gate and compare the efficiency of in vivo biotinylation of
the same target protein in the two different versions.
Retardation assays of the secretory (t-sIgE) and membrane
bound (t-mLIgE) molecules revealed that also in this case
most of them were biotinylated (Fig. 3A). No differences
in biotinylation levels were observed when the BAP
sequence was fused to the N- or the C-terminus of t-IgE:
indeed, in both forms the same ER luminal sequence is
present and they diverge in the position of the BAP tag.
The binding activity of the soluble biotinylated t-sIgE was
not compromised by biotinylation, as its efficient binding
to the high affinity FcεRI on RBL-SX38 cells was clearly
detected with streptavidin-Quantum Dots, both by flow
cytometry and immunofluorescence microscopy (Fig.
3B). Similarly, the membrane form t-mLIgE was effectively
displayed on the cell surface and efficiently biotinylated,
as revealed by fluorescent streptavidin binding (Fig. 3C).
Finally, we also expressed the BAP-tagged soluble version
of the FcεRI α-chain (αD1D2) [24], which became highly
biotinylated and retained its IgE binding activity (Fig. 4).
We tested the feasibility of purification of one of the in
vivo  biotinylated scFvs, using a commercially available
modified avidin with low binding affinity for biotin. As
shown in figure 5, the biotinylated scFv was eluted with
high yield and purity, and ten times concentrated with
respect to the culture supernatant.
As shown above, the ectopic localization in the ER of the
BirA enzyme did not compromise its enzymatic activity,
allowing biotinylation of both secretory and membrane
proteins. As expected, biotinylation was dependent on the
presence of the enzyme BirA in the right compartment. In
fact, only when the secreted scFv1E10 or t-sIgE were co-
expressed with sec-BirA, they became almost completely
biotinylated, whereas no biotinylation took place either
when scFv1E10  and t-sIgE were expressed alone or co-
expressed with cytosolic BirA (i.e: with no secretory signal
peptide). On the other hand, cytosolic BirA was compe-
tent, as expected, in biotinylating a cytoplasmic localized
protein, the rotavirus non-structural protein NSP5 [34]
(Fig. 6).
Discussion
The biotin-avidin/streptavidin binding is the strongest
non-covalent interaction known in nature. This property
is exploited as a biological tool for a wide range of appli-
cations, like purification or immunodetection of targetBMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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Biotinylation efficiency of secretory and membrane bound t-IgE Figure 3
Biotinylation efficiency of secretory and membrane bound t-IgE. (A) Western blot gel retardation assay of superna-
tants (t-sIgE) or cell extracts (t-mLIgE) from transiently transfected cells expressing secretory or membrane bound t-IgE. 
Where indicated, cell cultures were supplemented with biotin for 24 h and supernatants (dialyzed) or cell extracts reacted 
with streptavidin. (B) Flow cytometry and immunofluorescence microscopy assay on RBL-SX38 cells expressing human FcεRI 
incubated with biotinylated (red) or non-biotinylated (violet) t-sIgE; mAb 9E1 was detected with FITC-conjugated anti-mouse 
IgG antibody. (C) Flow cytometry and immunofluorescence microscopy assay of t-mLIgE displayed on transiently transfected 
HEK293T/17 cells, cultured in the presence (red) or absence (green) of biotin.BMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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molecules to which biotin is covalently attached. Most
approaches for biotinylation of molecules are based on
chemical procedures, which have as a major disadvantage
the lack of specifity for the biotin incorporation site.
Moreover, coupling reactions could modify residues that
affect the three-dimensional conformation or the specific
properties of the target molecule [8,9]. To overcome these
limitations, the enzymatic biotinylation was introduced
[35]. This technology was improved by the discovery of
new sequence specific substrates for biotinylation
enzymes that could be fused to the target molecules. Some
of these sequences are more than 100 amino acid long
[12], but shorter ones are also available. Among the lat-
ters, a very convenient one is the 15 amino acid long
biotin acceptor peptide (BAP), originally described by
Beckett et al. [14], which contains a single lysine as a
biotin acceptor residue. Biotinylation can be obtained in
vitro using proteins tagged with BAP and incubated with
the purified enzyme [6,36,37]; alternatively, a similar
strategy can be used in vivo by co-expressing the target pro-
tein and the biotin-protein ligase BirA. To co-express them
in mammalian cells, either a two plasmid co-transfection
Biotinylation of the soluble high affinity receptor FcεRI α-chain Figure 4
Biotinylation of the soluble high affinity receptor FcεRI α-chain. A) Western blot gel retardation assay of culture 
supernatants from cells expressing αD1D2. Where indicated, cell cultures were supplemented with biotin for 24 h and dia-
lyzed samples reacted with streptavidin. (B) ELISA on IgE-coated plates of αD1D2, revealed with anti-SV5 tag mAb or HRP-
conjugated streptavidin. (C) Flow cytometry and immunofluorescence microscopy assay with biotinylated (red) or non-bioti-
nylated (violet) αD1D2 on transfected A20 cells expressing human membrane IgE; the green signal corresponds to FITC-con-
jugated anti-human IgE (ε-chain specific) antibody.BMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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system has been used [15,18,38] or a bicistronic plasmid
based on the IRES sequence [39]. For this strategy to be
successful with proteins within the secretory pathway, the
BirA enzyme, which is a cytosolic protein, must be engi-
neered in a way that allows its translocation to the ER. We
achieved such translocation using a validated secretory
signal leader peptide from a mouse immunoglobulin
heavy chain [19]. This was essential since the cytosolic ver-
sion of BirA did not sustain biotinylation of secreted pro-
teins, while it did so very efficiently for cytosolic proteins
like rotavirus NSP5. Although a two-plasmid system can
be used, we arranged our system in a single bigenic plas-
mid, which was particularly useful for the selection of sta-
ble transfectomas co-expressing both proteins, and able to
sustain high levels of biotinylation. In addition, cell via-
bility was not compromised, allowing the continuous
production of the biotinylated molecule of interest.
Here we have shown the effective in vivo biotinylation of
different recombinant molecules of immunological inter-
est. However, this strategy can be applied to any other pro-
tein within the secretory pathway. The simple method we
used to induce BirA-driven high efficient biotinylation
was effective for a number of different secretory and mem-
brane bound proteins, with the BAP tag positioned both
at the C- and N-terminus. Fusion of the BAP peptide nei-
ther caused intracellular accumulation nor compromised
secretion of the scFvs  (data not shown). We have also
observed biotinylation of other proteins with BAP
inserted in defined structural internal loops (Arnoldi F.
and Burrone O.R., unpublished).
In order to get biotinylation strictly dependent on exoge-
nously added biotin, cells must be cultured in biotin-free
medium and dialyzed serum. This is an attractive aspect of
the technology, because it allows performing biotin pulse-
labelling, as well as production of non-biotinylated BAP-
tagged proteins.
Conclusion
This methodology provides many possibilities of applica-
tion. Biotinylated molecules obtained by transfection of
cells with the single bigenic plasmid can be simply recov-
ered and easily purified from the culture supernatants or
cell lysates using commercially available reagents, like
beads with covalently immobilised monomeric avidin,
from which bound proteins can be eluted using free
biotin. Furthermore, biotinylated membrane bound pro-
Purification of biotinylated scFv from culture supernatant Figure 5
Purification of biotinylated scFv from culture super-
natant. Western blot analysis of biotinylated scFvP3 purified 
in a low affinity avidin column and eluted with biotin, 
detected with anti-SV5 tag mAb (A) or with HRP-conjugated 
streptavidin (B). The eluted molecules (more than 90% of 
input) were about 10-fold more concentrated than in the 
supernatant.
Biotinylation dependence on BirA localization Figure 6
Biotinylation dependence on BirA localization. Western blot gel retardation assay on cells co-transfected with plasmid 
constructs encoding secretory (sec) or cytosolic (cyt) BirA, and scFv1E10 (A), t-sIgE (B) or NSP5 (C). Where indicated, superna-
tants (dialyzed) or cell extracts were reacted with streptavidin.BMC Biotechnology 2008, 8:41 http://www.biomedcentral.com/1472-6750/8/41
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teins can be easily detected on the surface of cells with
streptavidin conjugated with different fluorophores,
including Quantum Dots (which showed higher effi-
ciency). Moreover, culture supernatants containing bioti-
nylated secreted proteins can be directly used without
further purification in a number of different immuno-
chemical techniques, such as Western blot, ELISA,
immunofluorescence microscopy and flow cytometry.
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